|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM257971653 |
| 003 |
DE-627 |
| 005 |
20231224184004.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.02.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0859.xml
|
| 035 |
|
|
|a (DE-627)NLM257971653
|
| 035 |
|
|
|a (NLM)26928739
|
| 035 |
|
|
|a (PII)S1521-6616(16)30026-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Rosenberg, A S
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.08.2016
|
| 500 |
|
|
|a Date Revised 19.04.2016
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Published by Elsevier Inc.
|
| 520 |
|
|
|a Antibody responses to life saving therapeutic protein products, such as enzyme replacement therapies (ERT) in the setting of lysosomal storage diseases, have nullified product efficacy and caused clinical deterioration and death despite treatment with immune-suppressive therapies. Moreover, in some autoimmune diseases, pathology is mediated by a robust antibody response to endogenous proteins such as is the case in pulmonary alveolar proteinosis, mediated by antibodies to Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF). In this work, we make the case that in such settings, when the antibody response is high titered, sustained, and refractory to immune suppressive treatments, the antibody response is mediated by long-lived plasma cells which are relatively unperturbed by immune suppressants including rituximab. However, long-lived plasma cells can be targeted by proteasome inhibitors such as bortezomib. Recent reports of successful reversal of antibody responses with bortezomib in the settings of ERT and Thrombotic Thrombocytopenic Purpura (TTP) argue that the safety and efficacy of such plasma cell targeting agents should be evaluated in larger scale clinical trials to delineate the risks and benefits of such therapies in the settings of antibody-mediated adverse effects to therapeutic proteins and autoantibody mediated pathology
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Autoantibodies
|
| 650 |
|
4 |
|a Enzyme replacement therapy
|
| 650 |
|
4 |
|a Immune tolerance
|
| 650 |
|
4 |
|a Plasma cells
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Bortezomib
|2 NLM
|
| 650 |
|
7 |
|a 69G8BD63PP
|2 NLM
|
| 700 |
1 |
|
|a Pariser, A R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Diamond, B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yao, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Turka, L A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lacana, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kishnani, P S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 165(2016) vom: 16. Apr., Seite 55-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:165
|g year:2016
|g day:16
|g month:04
|g pages:55-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.02.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 165
|j 2016
|b 16
|c 04
|h 55-9
|